Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive

被引:59
作者
Hendrix, SL [1 ]
Alexander, NJ
机构
[1] Wayne State Univ, Detroit, MI 48201 USA
[2] Organon Pharmaceut Inc, W Orange, NJ 07052 USA
关键词
Mircette((R)); desogestrel; ethinyl estradiol; dysmenorrhea; prostaglandin; oral contraceptives; MDQ;
D O I
10.1016/S0010-7824(02)00414-6
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This randomized, double-blind, placebo-controlled exploratory study examined the efficacy and safety of a low-dose oral contraceptive. (Mircette(R)), desogestrel/ethinyl estradiol [DSG/EE] and ethinyl estradiol [EE]) in relieving the symptoms of dysmenorrhea. Twenty-three clinics in the United States enrolled 77 women (age less than or equal to32 years) with primary dysmenorrhea documented for at least four consecutive cycles. Forty participants received DSG/EE&EE and 37 received placebo for four consecutive 28-day cycles. The intensity of menstrual-related distress was measured with the Menstrual Distress Questionnaire (MDQ). Patient diaries were used to assess number of schoolwork days missed as well as the use of rescue medication. Participants receiving DSG/EE&EE recorded reduced menstrual pain severity, lower total MDQ scores, and significantly less menstrual cramping. No significant change in bloating, anxiety, loneliness, weight gain, or acne. was reported. The DSG/EE&EE formulation shows promise for the treatment of primary dysmenorrhea and was well tolerated by the participants in this study. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:393 / 399
页数:7
相关论文
共 19 条
[1]  
AKERLUND M, 1979, ACTA OBSTET GYN SCAN, P27
[2]  
AVANT RF, 1988, PRIMARY CARE, V15, P549
[3]   PROSTAGLANDINS IN PRIMARY DYSMENORRHEA - COMPARISON OF PROPHYLACTIC AND NONPROPHYLACTIC TREATMENT WITH IBUPROFEN AND USE OF ORAL-CONTRACEPTIVES [J].
CHAN, WY ;
DAWOOD, MY ;
FUCHS, F .
AMERICAN JOURNAL OF MEDICINE, 1981, 70 (03) :535-541
[4]  
DAWOOD MY, 1985, J REPROD MED, V30, P154
[5]  
DAWOOD MY, 1986, ACTA OBSTET GYN SCAN, P7
[6]   DYSMENORRHEA [J].
DAWOOD, MY .
CLINICAL OBSTETRICS AND GYNECOLOGY, 1990, 33 (01) :168-178
[7]   EFFECT OF AN ORAL-CONTRACEPTIVE IN PRIMARY DYSMENORRHEA - CHANGES IN UTERINE ACTIVITY AND REACTIVITY TO AGONISTS [J].
EKSTROM, P ;
JUCHNICKA, E ;
LAUDANSKI, T ;
AKERLUND, M .
CONTRACEPTION, 1989, 40 (01) :39-47
[8]   GESTODEN, AN INNOVATIVE PROGESTOGEN [J].
HOPPE, G .
CONTRACEPTION, 1988, 37 (05) :493-501
[9]   Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel:: Effects of low estrogen doses during the hormone-free interval [J].
Killick, SR ;
Fitzgerald, C ;
Davis, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) :S18-S24
[10]   Phase III clinical trial with a new oral contraceptive containing 150 mu g desogestrel and 20 mu g ethinylestradiol [J].
Lammers, Paul ;
op ten Berg, Monique .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1991, 70 (06) :497-500